Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
Go back to Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer| (NYSE: MYOV) | Delayed: 26.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.98 | 52 Week High | $15.50 | |||
| Open | $26.98 | 52 Week Low | $10.25 | |||
| Day High | $26.98 | P/E | N/A | |||
| Day Low | $26.98 | EPS | $0.00 | |||
| Volume | 1,750 | |||||
